MAP Pharmaceuticals (MAPP) Phase 3 Trial of LEVADEX Migraine Product Candidate Meets All Four Primary Endpoints
Up)
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- IsoRay (ISR) Says GliaSite System Received CE Mark; to Go On Sale in 31 European Markets
- Catalyst Pharmaceutical (CPRX) Reports Encouraging Data from CPP-115 Phase Ia
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
